Can a single ketamine infusion quiet the obsessive mind?

NCT ID NCT02624596

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether a single low dose of ketamine can quickly reduce obsessive-compulsive disorder (OCD) symptoms. Adults with OCD will receive either ketamine or a comparison drug, and researchers will measure symptom changes using a standard OCD scale. The trial also uses brain imaging to explore how ketamine affects brain chemistry, aiming to understand why it might work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ketamine (a single intravenous infusion)
What this could lead to
If successful, this could point toward a fast-acting treatment for OCD and reveal brain mechanisms behind symptom relief.
What could go wrong
This is a phase 2 trial with a single dose, so effects may be short-lived or not work for everyone. Ketamine can cause temporary side effects like dissociation or nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford University

    Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.